Alentis Aims To Put The Brakes On Fibrosis
Swiss Biotech's Series B Raises $67m
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
